Abbott's Humira does well in REVEAL trial

US drug major Abbott Laboratories presented positive data from a post-hoc analysis on the REVEAL trial of its Humira (adalimumab) in treating plaque psoriasis at the European Academy of Dermatology and Venereology congress in Paris, France.

The analysis of the 52-week, double blind, randomized, placebo-controlled Phase III trial was conducted to evaluate C-reactive protein concentrations in patients with moderate-to-severe psoriasis before and after treatment. 814 patients were given Humira and 398 patients placebo. 206 patients had elevated levels of CRP, 139 in the Humira group and 67 in the placebo group. After 16 weeks, 67% of the Humira group had normalized CRP levels, compared to only 37% of the placebo cohort.

Subgroup analyses showed that, after 16 weeks: among obese (Body Mass Index of 30 or above) patients, 64% in the Humira group had normal CRP levels versus 36% receiving placebo; and for patients with psoriatic arthritis, 72% in the Humira group had normal CRP levels, vs 43% in the placebo arm.